PRA023 for Systemic Sclerosis with Interstitial Lung Disease Request More Information Trial Objective Researchers are studying a new medication called PRA023 that has anti-inflammatory and antifibrotic properties to determine how well it works against systemic sclerosis (SSc) with interstitial lung disease (ILD). The goal of this study is to understand how safe and effective PRA023 is as a treatment option as compared to a placebo (an inactive substance that looks the same and is administered the same way as PRA023) for people for diagnosed with SSc-ILD. Study participants will receive monthly IV infusions and breathing tests, along with other assessments. If eligible, participants also may enter an open label extension for another 50 weeks, where they will receive active PRA023. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate People with a confirmed diagnosis of Systemic Sclerosis (SSc) with SSc-related Interstitial Lung Disease (ILD) Age: 18+ Gender: Any Gender Estimated Time Commitment Monthly visits over 50-week timeframe × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Available Trial Contact For more information, contact: Kris Eliopoulos 303.270.2622 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors Prometheus Biosciences Principal Investigators Mehrnaz Maleki Fischbach, MD + × Mehrnaz Maleki Fischbach, MD Associate Professor of Medicine Department of Medicine Division of Rheumatology View Full Profile Patient Rating 4.7 out of 5 stars Make an Appoinment Co-Investigators Liudmila Kastsianok, MD, RhMSUS + × Liudmila Kastsianok, MD, RhMSUS Assistant Professor Department of Medicine Division of Rheumatology View Full Profile Patient Rating 4.7 out of 5 stars Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective Researchers are studying a new medication called PRA023 that has anti-inflammatory and antifibrotic properties to determine how well it works against systemic sclerosis (SSc) with interstitial lung disease (ILD). The goal of this study is to understand how safe and effective PRA023 is as a treatment option as compared to a placebo (an inactive substance that looks the same and is administered the same way as PRA023) for people for diagnosed with SSc-ILD. Study participants will receive monthly IV infusions and breathing tests, along with other assessments. If eligible, participants also may enter an open label extension for another 50 weeks, where they will receive active PRA023.